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Available online 16 October 2012AbstractAims: Patients with locally advanced gastrointestinal stromal tumours (GISTs) have a high risk of tumour perforation, incomplete tumour
resections and often require multivisceral resections. Long-term disease-free and overall survival is usually impaired in this group of pa-
tients. Induction therapy with imatinib followed by surgery seems to be beneficial in terms of improved surgical results and long-term out-
come. We report on a large cohort of locally advanced GIST patients who have been treated in four centres in the Netherlands specialized in
the treatment of sarcomas.
Methods: Between August 2001 and June 2011, 57 patients underwent surgery for locally advanced GISTs after imatinib treatment. Data of
all patients were retrospectively collected. Endpoints were progression-free and overall survival.
Results: The patients underwent surgery after a median of 8 (range 1e55) months of imatinib treatment. Median tumour size before treat-
ment was 12.2 (range 5.2e30) cm and reduced to 6.2 (range 1e20) cm before surgery. No tumour perforation occurred and a surgical
complete (R0) resection was achieved in 48 (84%) patients. Five-year PFS and OS were 77% and 88%. Eight patients had recurrent/met-
astatic disease.
Conclusions: Imatinib in locally advanced GIST is feasible and enables a high complete resection rate without tumour rupture. The com-
bination of imatinib and surgery in patients with locally advanced GIST seems to improve PFS and OS.
 2012 Elsevier Ltd.
Keywords: Gastrointestinal stromal tumour; Surgery; Imatinib
Open access under the Elsevier OA license.Introduction
Gastrointestinal stromal tumours (GISTs) are the most
common soft tissue tumours of the gastrointestinal tract,
which arise from the interstitial cells of Cajal.1 The esti-
mated prevalence is 1e2 per 100 000 persons.2,3 Most
GISTs express KIT, a tyrosine kinase receptor, which can
be detected by immunohistochemistry using the CD117* Corresponding author. Tel.: þ31 24 361 3808; fax: þ31 24 354 0501.
E-mail address: r.tielen@chir.umcn.nl (R. Tielen).
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Open access under the Elsevier OA license.antibody.1 Over 80% of GISTs have an activating mutation
in the KIT or, less often, the PDGFRA gene.4e6
Historically, treatment for locally advanced GISTs has
relied on surgery as the first-line intervention, as response
rates to conventional chemotherapy were less than
10%.7,8 Approximately 70e85% of GISTs are primary re-
sectable at first presentation depending on anatomic site
and/or tumour size. A high mitotic activity, large tumour
size, incomplete surgical resection and tumour perforation
have been identified as negative prognostic factors for re-
lapse and survival.1,3,9e11
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tyrosine kinase inhibitor, was found to inhibit mutated
KIT or PDGFA receptor tyrosine kinases.12,13 Imatinib
has been demonstrated to achieve partial response or stable
disease in nearly 80% of patients with advanced GIST.12e14
Treatment with imatinib is generally well-tolerated with
mild side effects and is considered first-line treatment in
metastasized GIST patients.14 Nevertheless, progression
of disease occurs at a median time of 2 years from start
of treatment through acquisition of additional activating
c-KIT or PDGFA mutations in tumour clones rendering
them imatinib refractory.15,16
Before the era of imatinib, surgical resection of locally
advanced GISTs larger than 5 cm resulted in a median over-
all survival (OS) of approximately 30 months and a recur-
rence rate of up to 60% within 2 years.7e9 Because imatinib
induces downsizing of large tumours, it could potentially
reduce the risk of tumour rupture during surgery and pro-
vide an opportunity for a surgical complete and less morbid
(i.e. organ-sparing) resection.17 This could lead to an im-
proved disease-free and overall survival in patients with lo-
cally advanced GISTs. Reports on surgical resection
following imatinib treatment in patients with locally ad-
vanced GIST are limited and usually consist of small retro-
spective patient series.17e22 Most of these studies also
included patients with both locally advanced and metastatic
disease. The present study is the first to retrospectively
evaluate the long-term outcome in a large group of patients
who underwent surgery for locally advanced, non-
metastatic, GIST after treatment with imatinib.
MethodsPatients and preoperative treatmentWe reviewed all patients with a locally advanced GIST
who received imatinib before surgery was undertaken at
four Dutch institutions (The Netherlands Cancer Institute,
Amsterdam; Leiden University Medical Centre, Leiden;
Radboud University Nijmegen Medical Centre, Nijmegen;
Erasmus Medical Centre, Daniel Den Hoed Cancer Centre,
Rotterdam). These patients were evaluated in a multidisci-
plinary sarcoma board at each centre before start of treat-
ment. All tumours were considered too large (>5 cm)
and/or ill-located for surgery by the sarcoma board. There-
fore, imatinib was started in an attempt to downsize the tu-
mour and prevent peroperative tumour rupture with
a possibly less mutilating resection. Before start of imatinib
a baseline CT was performed, and all patients were clini-
cally and radiographically re-evaluated until surgery. Pa-
tients were classified as having a complete response (CR),
partial response (PR), stable disease (SD) or progressive
disease (PD) on the use of imatinib, based on serial imaging
and scored according to Response Evaluation Criteria in
Solid Tumours (RECIST).23 The decision when to perform
surgery was tailor-made for each patient at the time themultidisciplinary sarcoma board thought of a maximum
therapeutic response.
We collected patient- and treatment-specific data from
prospectively kept sarcoma databases, medical records da-
tabases and patient charts at every institution. Data included
initial symptoms, date of diagnosis, histopathological anal-
yses, duration and dose of imatinib, complications on ima-
tinib, best response to imatinib, date of surgery, type of
surgical resection and (postoperative) complications, adju-
vant imatinib treatment, date of recurrent/metastatic disease
after surgery, last follow-up and disease status at last
follow-up, and if applicable, date of death.Surgery and postoperative treatmentAll resections were classified as R0 (macroscopically
complete resection with negative microscopic margins),
R1 (macroscopically complete resection with positive mi-
croscopic margins) or R2 (macroscopically incomplete re-
section). Recurrent disease appearing after surgery in the
region of the previously located tumour is called ‘recur-
rence’, and disease that had spread to distant sites, such
as the liver, is called ‘metastasis’. Imatinib treatment was
restarted depending on completeness of resection and pref-
erence of the treating physicians. Status of disease at last
follow-up was determined using the most recent physical
and radiographical evaluation. If a patient had deceased,
date of death and status of disease at death were recorded.
The data of each patient was updated until July 2011.Endpoints and statisticsProgression-free survival (PFS) was defined as the time
from date of surgery to the date of clinical evidence of re-
current or metastatic disease, date of last follow-up or death
from any cause, whatever occurred first. OS was defined as
the time from surgery to date of last follow-up or patient
death. PFS and OS were estimated using the KaplaneMeier
method. Statistical analysis was performed using SPSS sta-
tistical software, version 16.0.
ResultsPatients and preoperative imatinib treatmentA total of 57 patients (35 men and 22 women) were el-
igible for evaluation. The median age was 61 (range
29e82) years at the time of surgery after treatment with im-
atinib. Details on tumour location and imatinib treatment
are summarized in Table 1. All GISTs were confirmed by
experienced sarcoma pathologists at each centre and were
characterized by a positive c-KIT expression. Other tumour
markers were not commonly assessed. Mutation status was
available in 30 patients: KIT exon 11 (n ¼ 18), KIT exon 9
(n ¼ 1), KIT exon 12 mutation (n ¼ 1), KIT exon 18 mu-
tation (n ¼ 1), KIT exon 9 and 17 mutation (n ¼ 1),
Table 1
Tumour location and initial therapy details.
n ¼ 57
Primary location
Stomach 37
Duodenum 2
Small intestine 6
Rectum 12
Preoperative imatinib therapya
Imatinib 400 50
Imatinib 400, switch 300b 2
Imatinib 400, switch 800c 5
a In mg daily dose.
b Decreased dose due to complications.
c Increased dose due to progressive disease.
Table 2
Operative procedures.
Procedures No.
Gastrectomy 22
Gastrectomy þ splenectomy þ pancreatectomy  bowel resection 14
Small bowel resection  bowel resection 6
Abdominoperineal resection 5
Duodenal resection 2
Rectosigmoid resection 1
Intersphincteric rectum amputation 1
Partial rectum resection 3
Exploratory laparotomya 1
Total/posterior exenteration 2
a Resection was not possible.
Table 3
Postoperative complications.
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the remaining 27 patients, the mutation status was not de-
termined because it was not routinely performed in the
past or analysis was not possible due to technical difficul-
ties. Median tumour size was 12.2 (range 5.2e30) cm be-
fore start of imatinib. Treatment with imatinib 400 mg
daily was the first choice of treatment in all patients. The
primary tumour size, possible invasion of surrounding or-
gans on CT-imaging and technical difficult surgical proce-
dures (i.e. ill-location), surgery was not the first choice in
treatment. Two patients experienced gastrointestinal com-
plications and imatinib was lowered to 300 mg daily before
surgery. Two patients with a PR had to stop using imatinib
after 1 and 4 months because of severe toxidermic compli-
cations and progressive (pre-existent) renal failure. Surgery
followed within two weeks after stopping imatinib. Two pa-
tients shortly interrupted imatinib because of gastrointesti-
nal complications and oedema, after a short stop imatinib
was continued at 800 mg daily dose because of disease pro-
gression. Three patients experienced disease progression
from start of imatinib and switched to 800 mg daily. Two
patients experienced a PR and one patient PD after starting
the higher dose and surgery followed after 2, 2, and 4
months, respectively. No patient was switched to second-
line therapy. The tumour size after a median of 8 (range
1e55) months of treatment with imatinib was 6.2 (range
1e20) cm. One patient had a CR, 46 patients had a PR, 7
patients had SD and 3 patients had PD at the time of sur-
gery. One patient experienced an ongoing (partial) response
before disease stabilization at 51 months. Surgery followed
at 55 months.Complications No.
Intra-abdominal bleeding 4Surgical outcome and postoperative treatment
Anastomotic leakagea 2
Bowel perforation 1
Urinary tract infection 3
Enterocutaneous fistula 1
Gastric perforation 1
Abscess 2
Wound infection 5
Fascial dehiscence 1
a Involved anastomotic leakage of large bowel segments.All patients underwent elective surgery and the proce-
dures are listed in Table 2. In 6 patients no viable tumour
could be demonstrated at final pathology. An R0 resection
was achieved in 48 patients and an R1 resection in 8 pa-
tients. In 1 patient, resection of the tumour was not consid-
ered feasible during surgery because of extensive tumour
invasion in liver, spleen, pancreas and duodenum. Despitetumour shrinkage 19 patients were surgically treated with
an en-bloc multivisceral resection. In the other patients,
a less mutilating procedure was performed. One patient un-
derwent a partial resection of the anterior wall of the rec-
tum because the tumour was located between the prostate
and rectum. The tumour was removed without performing
a low anterior resection. Thirteen patients experienced at
least one surgical complication, with a total of 20 compli-
cations (Table 3). Reoperations for complications were re-
quired in four patients; postoperative bleeding (one), bowel
perforation (one), and anastomotic leakage of large bowel
(two). No postoperative mortality was observed within 30
days of surgery. One patient with a bowel perforation
died 44 days after surgery. In 33 patients, imatinib was con-
tinued following surgery for 1, 2 years or lifelong after
evaluation in the sarcoma board.Progression-free and overall survivalComplete follow-up data were available for 55 patients.
Two 2 patients were lost to follow-up. Median PFS mea-
sured from time of surgery has not been reached, and
one-, three- and five-year PFS have been estimated at
96%, 87% and 77%. Eight patients experienced recurrent/
metastatic disease; 3 patients during adjuvant imatinib
treatment and 5 patients without adjuvant imatinib treat-
ment. These five patients were treated with imatinib at
the time of diagnosis of recurrent/metastatic disease. PFS
based on adjuvant imatinib treatment is shown in Fig. 1.
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Figure 1. Progression-free survival (PFS) for patients treated adjuvant with
imatinib (Group A) and patients not treated adjuvant with imatinib (Group
B), calculated from date of surgery (months).
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Figure 2. Overall survival (OS) of operated patients, calculated from start
of imatinib (months).
Table 4
Outcome of patients treated with imatinib followed by surgery for locally
advanced GIST.
Author No. of
patients
Follow-up
(median/months)
Survival and disease
status
Andtbacka
et al., 200620
11 19.5 All alive at last
follow-up; 10 NED,
1 RD
Raut et al., 200621 9 14.6a 95% 1-year survival
SD, 86% 1-year
survival LP, 0% 1-year
survival GPa
Mearadji
et al., 200819
9 40 All alive at last FU;
7 NED, 2 AWD
Eisenberg
et al., 200917
30 36 83% 2-year PFS, 93%
2-year OS
Fiore et al., 200918 15 34 14 alive at last FU:
12 NED, 2 RD, 1 DD
Blesius
et al., 201122
9 53.5 67% 3-year PFS,
89% 3-year OS
Present study 57 43 47 alive at last FU,
4 AWD, 3 DD
NED, no evidence of disease; RD, recurrent disease; AWD, alive with dis-
ease; DD, died of disease.
a Patients were divided in three categories: stable disease (SD), limited
progression (LP), and generalized progression (GP).
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group was shown, it was not significantly different
( p ¼ 0.11). Seven patients developed distant metastasis:
peritoneal (n ¼ 4), liver (n ¼ 1), peritoneal and liver
(n ¼ 1) and abdominal wall (n ¼ 1). One patient experi-
enced a local recurrence after an intersphincteric rectum
amputation. Surgical procedures were performed in three
patients because of metastatic lesions. One patient under-
went resection of several metastatic peritoneal lesions and
a splenectomy 11 months after initial surgery, and has no
evidence of disease 23 months after initial surgery. One pa-
tient underwent a partial liver resection 26 months after re-
section of the primary tumour. Because of re-recurrent
metastases, radiofrequency ablation of liver metastases
and resection of 2 peritoneal metastatic lesions combined
with a partial small bowel resection was performed after
51 months. This patient died of disease 59 months after ini-
tial surgical treatment. Finally, one patient underwent re-
section of abdominal wall metastases and resection of 2
peritoneal lesions 9 months after initial surgery. This pa-
tient is alive without evidence of disease.
At recent follow-up, 44 patients had no evidence of dis-
ease, 4 patients were alive with disease, 4 patients had died
of disease and 3 patients died because of other reasons. Me-
dian OS has not been reached, one-, three-, and five-year
OS have been estimated at 100%, 96% and 88% (Fig. 2).
Four patients died of GIST. No correlation between clini-
cal, pathological, and treatment variables with prognosis
could be demonstrated due to small sample size.
Discussion
This study is the largest study to date to report long-term
outcome of patients who underwent surgical resection of
locally advanced, non-metastatic GIST after imatinib ther-
apy. Larger studies are available reporting the results of
both locally advanced and metastatic GIST together as
one group with or without surgery after imatinib therapy,
which makes it difficult to compare with the results of
this study.15,20 Several reports differentiate between locally
advanced and metastatic GIST, but are usually comprisedof small patient series with a limited follow-up (Table 4).
The present series demonstrates a high 5-year PFS and
OS of 77% and 88% in a multicentre collected group of pa-
tients with locally advanced GISTs.
Surgery remains the only possible curative treatment for
GIST. Approximately 70e85% of patients with localized
GISTs can undergo a complete resection at first presenta-
tion.7,24 A surgical complete resection is the most important
prognostic factor for patients with locally advanced, non-
metastatic GIST. Furthermore, large tumours carry an in-
creased risk of tumour rupture, which has a detrimental ef-
fect on disease-free and overall survival. Tumour rupture
reduced the median survival to approximately 17 months,
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complete resection in the pre-imatinib era as reported by Ng
et al.9 Recently, Hohenberger et al. reported that nearly all
patients develop abdominal metastases after rupture of
GIST.11 Therefore, if a GIST is large and the risk of tumour
rupture is considered high, imatinib treatment should be
started to increase the chance of an R0 resection and decrease
the potential risk of tumour perforation during surgery.
The discovery of gain-of-function KIT mutations in
GIST by Hirota et al. and the introduction of imatinib,
the small-molecular targeted therapy, revolutionized the
management of GIST.4,12 Currently, imatinib is approved
worldwide as the first-line treatment of metastatic GIST.
Toxicity and primary resistance to imatinib are the main
limitations of this drug.13,25 Secondary resistance, defined
as progressive disease at least 3 months after initiation of
imatinib, usually occurs at a median time of 2 years after
start of treatment.13 Timing of resection is important if im-
atinib is used as induction therapy in locally advanced tu-
mours. If surgery is performed beyond the window of
therapeutic response, resistance or metastases might de-
velop.15 In the present study, the median interval between
start of imatinib and surgery was 8 months, and no patient
switched to second-line therapy because of disease progres-
sion. This might indicate that all tumours reached a plateau
in their response to imatinib. A favourable outcome for re-
sponding patients undergoing surgery following imatinib
has already been suggested in metastasized patients.19e21
Although this has not been confirmed in a randomized trial.
In this study, tumour response on imatinib has been as-
sessed by a combination of physical and radiological exam-
ination. A partial response on CT scan according to
RECIST requires at least 6 months of imatinib therapy.15
Using size-based response criteria such as RECIST might
underestimate the response to imatinib as suggested by
clinical experience in the last few years.26,27 Changes in tu-
mour nodules and vascularization should be combined with
tumour density and smaller changes in size to evaluate po-
tential responses by CT faster. A positron emission tomog-
raphy (PET) using 18F-fluorodeoxyglucose (18FDG) may
predict responses to therapy better on short-term follow-
up. It is instrumental when CT findings are inconsistent
with clinical findings.26,28,29 Response measurement using
these 18FDG-PET scan criteria was not always possible be-
cause of the retrospective nature of this study. Most patients
were diagnosed with GIST in other hospitals and an 18FDG-
PET scan was not always available.
Given the anti-tumour activity of imatinib in the meta-
static setting, with response rates of over 50%, imatinib is in-
creasingly used. In patients with locally advanced GISTs, i.e.
when resection is judged impossible or at the cost of consid-
erable morbidity, it is now commonly used as induction ther-
apy. Randomized controlled studies are hard to conduct for
multiple reasons and the only prospective multicentric neo-
adjuvant imatinib trial was the RTOG study.17 A better in-
sight needs to be obtained by retrospective series. In thepresent study, adequate clinical downsizing of the tumour
with preoperative imatinib therapy was demonstrated in 52
patients who underwent an R0 resection without tumour per-
foration. This reflects the main advantage of imatinib as in-
duction therapy in patients with locally advanced GIST. A
less extensive resection rate was not clearly demonstrated
in this study as 19 patients underwent multivisceral resec-
tions. However, most multivisceral resections (n ¼ 14)
were performed in the early treated patients and after 2007
less extensive resections have become more common. This
bias is probably caused by increased knowledge of the poten-
tial benefits of imatinib and the tendency of locally advanced
GIST not to invade surrounding organs.
At a median postoperative follow-up time of 40 months,
the 5-year estimated PFS was 77% measured from surgery.
This seems an improvement compared to historical data,
since patients with tumours larger than 10 cm experienced
a disease-specific 5-year survival of only 20% after resec-
tion in recent literature.7,8 However, this comparison is bi-
ased because 33 patients received adjuvant treatment with
imatinib. Median PFS for patients treated with adjuvant im-
atinib has not been reached and for patients who received
no adjuvant treatment it was 49 (range 9e56) months. In
a phase III trial, patients with GISTs larger than 3 cm un-
derwent surgical resection and received adjuvant imatinib
or placebo for 1 year.25 Significantly fewer recurrences
were noted in patients who received imatinib for 1 year
after complete resection compared to patients receiving
placebo. Median recurrence-free survival was not reached
for tumours between 6 and 10 cm, and median
recurrence-free survival for tumours 10 cm or greater was
approximately 35 months in the imatinib group. Recently,
Joensuu et al. reported that administration of imatinib for
36 months after surgery improves recurrence-free and over-
all survival compared to 12 months in patients with a high
estimated risk of recurrence.30 Although these results have
to be published, adjuvant treatment with imatinib is now
considered standard treatment in the referral hospitals of
this study group.
Median OS after surgical resection of GISTs larger than
5 cm is reported to be approximately 27e32 months.7-9 The
OS in the present study is substantially higher with 83% of
patients alive at 5 years, and median OS not reached after
49 months. This might suggest that imatinib therapy fol-
lowed by surgical resection enables adequate surgical re-
sections with a low chance on tumour perforation and
might prolong OS. Once again, firm conclusions are hard
to draw as the current median OS of patients with meta-
static disease treated with imatinib and/or sunitinib has
meanwhile dramatically improved as well.
Conclusion
Evaluation of patients with a locally advanced, non-
metastatic GIST in a multidisciplinary tumour board in
high-volume GIST centres has proven to be successful. It
155R. Tielen et al. / EJSO 39 (2013) 150e155supplies the best strategy for treatment and prevention of
disease progression. Imatinib as induction therapy is con-
sidered a useful tool in patients with locally advanced
GIST. This results in a decrease of tumour size in most pa-
tients, and thereby increases the chances of a surgical com-
plete resection without tumour rupture. Combining imatinib
and surgery in patients with locally advanced GIST seems
to improve PFS and OS compared to available historical re-
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